Novo Nordisk recently faced a significant blow when its trials for an older version of its semaglutide drug failed to show any benefits in slowing Alzheimer’s disease. This news caused the company’s shares to drop by 10%. These trials, which were aimed at testing the drug’s effectiveness in slowing cognitive decline, were viewed as a possibility for a new market for semaglutide, previously known only for treating obesity and diabetes.
Erik Berg-Johnsen from Storebrand Asset Management remarked that the trial failure might represent a “nail in the coffin” for any hopes of using semaglutide for Alzheimer’s. The study, which was already seen as uncertain in its potential, was designed to assess cognitive improvements over two years but had to be stopped after the first two years showed little promise.
Alzheimer’s affects over 55 million people worldwide, and current treatments are limited. Biogen’s Leqembi and Eli Lilly’s treatment are the only approved options in the United States, which involve complicated administration and can cause significant side effects.
The trials aimed for a 20% slowdown in cognitive decline and involved nearly 3,800 early-stage Alzheimer’s patients. Analysts had expressed caution over the high-risk nature of these trials and were closely watching for any positive results that could potentially reshape the Alzheimer’s treatment landscape.
Analysts like Henrik Hallengreen Laustsen from Jyske Bank explained that the drop in shares was not entirely unexpected, considering Novo Nordisk’s challenging year marked by increasing competition and management changes. He noted that the reactions from investors likely stemmed from an overarching negative sentiment toward the company’s recent performance.
Recent data highlights an increasing market for Alzheimer’s treatments. A report estimated that global sales of Alzheimer’s drugs could reach $23 billion by 2028. Despite this, Novo’s hopes of entering this market with semaglutide appear dashed.
While semaglutide did not prove effective for Alzheimer’s, its benefits for diabetes and obesity remain strong, as emphasized by Chief Scientific Officer Martin Holst Lange. Although the current trials were a setback, they shed light on future opportunities in the Alzheimer’s drug market, which remains a critical area of research as we seek better treatments for a disease that affects millions.
As the conversation continues in healthcare circles, it’s crucial to keep an eye on how existing Alzheimer’s treatments hold up against emerging contenders in the market. For those interested, you can read more about Novo Nordisk’s ongoing research initiatives here.
Source link
RSBI:REGULATORY-OVERSIGHT,RHPI:REGULATORY,CMPNY,DEMENT,DIABET,ENDOCR,GEN,HEA,HECA,HUMDIS,LSCI,MEDREG,NEUROL,NEWS1,OBESIT,PHAR,PHAR1,PHMR,PUBL,REGS,SCI,WEU,AMERS,SCANDV,US,EUROP,SE,DK,NO,NORD,EZC,NAMER,EMEA,FI,DEST:OUSHEM,TOPIC:PHARMA-HEALTHCARE-POLICY-REGULATION,HOT,STX,DEST:NW,DEST:CSA,DEST:LBY,DEST:REULB,DEST:ABX,DEST:G,DEST:RAST,DEST:SOF,DEST:M,DEST:SW,DEST:E,DEST:C,DEST:ABN,DEST:AFA,DEST:BNX,DEST:GRO,DEST:PSC,DEST:U,DEST:O,DEST:DA,DEST:MTL,DEST:FN,DEST:FUN,DEST:UCDPTEST,DEST:RWSA,DEST:GNS,DEST:RWS,DEST:D,DEST:RBN,DEST:OIL,DEST:OUKTPM,MTVID,TOPNWS,RHPI:BIOPHARMA,TOPIC:PHARMA-HEALTHCARE-BUSINESS-HEALTH,BIOPH,MRCH,EASIA,ASXPAC,ASIA,JP,DEST:J,TOPCMB,DEST:OUSBSM,DEST:OCABSM
